Patents by Inventor Shaw-Fen Sylvia Hu

Shaw-Fen Sylvia Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human CGRP receptor binding proteins
    Patent number: 12134652
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: November 5, 2024
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Human CGRP receptor binding proteins
    Patent number: 12122841
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: October 22, 2024
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Human antigen binding proteins that bind ?-klotho, FGF receptors and complexes thereof
    Patent number: 12116413
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: October 15, 2024
    Assignee: AMGEN INC.
    Inventors: Shaw-Fen Sylvia Hu, Ian Nevin Foltz, Chadwick Terence King, Yang Li, Taruna Arora
  • Antigen binding proteins that bind to a complex comprising ?-Klotho and an FGF receptor
    Patent number: 11248052
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing ?-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: February 15, 2022
    Assignee: AMGEN INC.
    Inventors: Yang Li, Jennitte LeAnn Stevens, Chadwick Terence King, Ian Nevin Foltz, Gunasekaran Kannan, Junming Yie, Shaw-Fen Sylvia Hu
  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20210179722
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20210179723
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, Jr., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • Human Antigen Binding Proteins That Bind Beta-Klotho, FGF Receptors and Complexes Thereof
    Publication number: 20200216546
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Application
    Filed: January 16, 2020
    Publication date: July 9, 2020
    Applicant: Amgen, Inc.
    Inventors: Shaw-Fen Sylvia HU, Ian Nevin FOLTZ, Chadwick Terence KING, Yang LI, Taruna ARORA
  • Human antigen binding proteins that bind ?-Klotho, FGF receptors and complexes thereof
    Patent number: 10570205
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: February 25, 2020
    Assignee: Amgen, Inc.
    Inventors: Shaw-Fen Sylvia Hu, Ian Nevin Foltz, Chadwick Terence King, Yang Li, Taruna Arora
  • Methods and compositions relating to anti-CCR7 antigen binding proteins
    Patent number: 10526411
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 7, 2020
    Assignee: Amgen Inc.
    Inventors: Chadwick Terence King, Gordon Ng, Shaw-Fen Sylvia Hu, Hung Nguyen, Jeannie Jung
  • Human Antigen Binding Proteins That Bind to a Complex Comprising Beta-Klotho and an FGF Receptor
    Publication number: 20190248906
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Applicant: Amgen, Inc.
    Inventors: Yang LI, Jennitte LeAnn STEVENS, Chadwick Terence KING, Ian Nevin FOLTZ, Gunasekaran KANNAN, Junming YIE, Shaw-Fen Sylvia HU
  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20180142029
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: November 28, 2017
    Publication date: May 24, 2018
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • Human CGRP receptor binding proteins
    Patent number: 9862771
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 9, 2018
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • METHODS AND COMPOSITIONS RELATING TO ANTI-CCR7 ANTIGEN BINDING PROTEINS
    Publication number: 20170342155
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 30, 2017
    Applicant: AMGEN INC.
    Inventors: Chadwick Terence KING, Gordon NG, Shaw-Fen Sylvia HU, Hung NGUYEN, Jeannie JUNG
  • Human Antigen Binding Proteins That Bind To a Complex Comprising beta-Klotho and an FGF Receptor
    Publication number: 20170183412
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.
    Type: Application
    Filed: January 6, 2017
    Publication date: June 29, 2017
    Inventors: Yang LI, Jennitte LeAnn STEVENS, Chadwick Terence KING, Ian Nevin FOLTZ, Gunasekaran KANNAN, Junming YIE, Shaw-Fen Sylvia HU
  • Human antigen binding proteins that bind to a complex comprising ?-Klotho and an FGF receptor
    Patent number: 9574002
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: February 21, 2017
    Assignee: AMGEN INC.
    Inventors: Yang Li, Jennitte Stevens, Chadwick Terence King, Ian Foltz, Gunasekaran Kannan, Junming Yie, Shaw-Fen Sylvia Hu
  • HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETTA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF
    Publication number: 20170015750
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Applicant: AMGEN INC.
    Inventors: Shaw-Fen Sylvia HU, Ian Nevin FOLTZ, Chadwick Terence KING, Yang LI, Taruna Arora
  • Human FGF receptor and ?-Klotho binding proteins
    Patent number: 9517264
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: December 13, 2016
    Assignee: AMGEN INC.
    Inventors: Roger Fachini, Ian Foltz, Seog Joon Han, Susie Miki Harris, Shaw-Fen Sylvia Hu, Chadwick Terence King, Yang Li, Ji Lu, Mark Leo Michaels, Jeonghoon Sun
  • Human antigen binding proteins that bind ?-klotho, FGF receptors and complexes thereof
    Patent number: 9493577
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: November 15, 2016
    Inventors: Shaw-Fen Sylvia Hu, Ian Nevin Foltz, Chadwick Terence King, Yang Li, Taruna Arora
  • HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF
    Publication number: 20160145351
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Application
    Filed: February 2, 2016
    Publication date: May 26, 2016
    Inventors: Shaw-Fen Sylvia HU, Ian Nevin FOLTZ, Chadwick Terence KING, Yang LI, Taruna Arora
  • Human antigen binding proteins that bind ?-Klotho, FGF receptors and complexes thereof
    Patent number: 9284378
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: March 15, 2016
    Inventors: Shaw-Fen Sylvia Hu, Ian Foltz, Chadwick Terence King, Yang Li, Taruna Arora